JPWO2022232494A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022232494A5 JPWO2022232494A5 JP2023566515A JP2023566515A JPWO2022232494A5 JP WO2022232494 A5 JPWO2022232494 A5 JP WO2022232494A5 JP 2023566515 A JP2023566515 A JP 2023566515A JP 2023566515 A JP2023566515 A JP 2023566515A JP WO2022232494 A5 JPWO2022232494 A5 JP WO2022232494A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- degrees
- dose
- subject
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 151
- 238000000034 method Methods 0.000 claims description 115
- 150000003839 salts Chemical class 0.000 claims description 56
- 238000011282 treatment Methods 0.000 claims description 49
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 26
- 210000004251 human milk Anatomy 0.000 claims description 26
- 235000020256 human milk Nutrition 0.000 claims description 26
- 201000009916 Postpartum depression Diseases 0.000 claims description 24
- 208000024714 major depressive disease Diseases 0.000 claims description 24
- 239000012458 free base Substances 0.000 claims description 21
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 230000036506 anxiety Effects 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 238000011283 initial treatment period Methods 0.000 claims description 6
- 206010001497 Agitation Diseases 0.000 claims description 5
- 206010022998 Irritability Diseases 0.000 claims description 5
- 206010024264 Lethargy Diseases 0.000 claims description 5
- 208000032140 Sleepiness Diseases 0.000 claims description 5
- 206010041349 Somnolence Diseases 0.000 claims description 5
- 206010047897 Weight gain poor Diseases 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 230000000474 nursing effect Effects 0.000 claims description 5
- 230000037321 sleepiness Effects 0.000 claims description 5
- 230000001430 anti-depressive effect Effects 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 229940046011 buccal tablet Drugs 0.000 claims description 4
- 239000006189 buccal tablet Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 206010054089 Depressive symptom Diseases 0.000 claims description 3
- 230000004596 appetite loss Effects 0.000 claims description 3
- 208000019017 loss of appetite Diseases 0.000 claims description 3
- 235000021266 loss of appetite Nutrition 0.000 claims description 3
- 235000019789 appetite Nutrition 0.000 claims description 2
- 230000036528 appetite Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 28
- 239000003814 drug Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181807P | 2021-04-29 | 2021-04-29 | |
| US63/181,807 | 2021-04-29 | ||
| PCT/US2022/026908 WO2022232494A1 (en) | 2021-04-29 | 2022-04-29 | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515830A JP2024515830A (ja) | 2024-04-10 |
| JP2024515830A5 JP2024515830A5 (https=) | 2025-05-09 |
| JPWO2022232494A5 true JPWO2022232494A5 (https=) | 2025-05-09 |
Family
ID=81748326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566515A Pending JP2024515830A (ja) | 2021-04-29 | 2022-04-29 | 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240216396A1 (https=) |
| EP (1) | EP4329769A1 (https=) |
| JP (1) | JP2024515830A (https=) |
| CN (1) | CN117580580A (https=) |
| AU (1) | AU2022267304A1 (https=) |
| CA (1) | CA3217866A1 (https=) |
| IL (1) | IL307980A (https=) |
| MX (1) | MX2023012728A (https=) |
| WO (1) | WO2022232494A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CN113939298A (zh) * | 2018-12-14 | 2022-01-14 | 普拉西斯精密医药公司 | 用于治疗抑郁症的方法 |
| US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
-
2022
- 2022-04-29 US US18/557,705 patent/US20240216396A1/en active Pending
- 2022-04-29 CN CN202280045723.6A patent/CN117580580A/zh active Pending
- 2022-04-29 AU AU2022267304A patent/AU2022267304A1/en active Pending
- 2022-04-29 CA CA3217866A patent/CA3217866A1/en active Pending
- 2022-04-29 JP JP2023566515A patent/JP2024515830A/ja active Pending
- 2022-04-29 MX MX2023012728A patent/MX2023012728A/es unknown
- 2022-04-29 IL IL307980A patent/IL307980A/en unknown
- 2022-04-29 EP EP22724194.0A patent/EP4329769A1/en active Pending
- 2022-04-29 WO PCT/US2022/026908 patent/WO2022232494A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527092A5 (https=) | ||
| JP2012531446A (ja) | 気管支炎を治療するための麻黄含有医薬組成物およびその調製方法 | |
| EP0705099A1 (fr) | Utilisation du modafinil pour le traitement des apnees du sommeil et troubles ventilatoires d'origine centrale | |
| JP2020534270A5 (https=) | ||
| CN113304166A (zh) | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 | |
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| JPWO2022232494A5 (https=) | ||
| RU2009119258A (ru) | Способ лечения воспалительных заболеваний кишечника | |
| JPWO2023054732A5 (https=) | ||
| JPWO2019241442A5 (https=) | ||
| JPWO2021168403A5 (https=) | ||
| WO2002078691A1 (en) | Duloxetine for treatment of hot flashes | |
| JP2006505548A (ja) | Ｐｐａｒリガンドと抗酸化剤の会合および肥満の治療のためのその使用 | |
| JPWO2019232130A5 (https=) | ||
| TW200918094A (en) | Pharmaceutical acceptable composition containing non-steroidal anti-inflammatory drug and local anesthetics | |
| KIERLAND et al. | Cortisone and corticotropin (ACTH) in treatment of scleroderma | |
| JP2021530568A5 (https=) | ||
| RU2721409C1 (ru) | Фармацевтические комбинации ингибитора гистондеацетилаз и ингибитора протеасом или иммуномодулирующего лекарственного средства для лечения рака крови | |
| EP4613275A1 (en) | Pharmaceutical use of nucleoside compound | |
| JPWO2022232504A5 (https=) | ||
| CN107281386A (zh) | 以铁皮石斛与莱菔子制备治疗高血压药物的方法及应用 | |
| JPWO2021202825A5 (https=) | ||
| CN110841069A (zh) | 一种含有沙利度胺与抗真菌药物的药物组合物及应用 | |
| JPWO2020176432A5 (https=) | ||
| CN116712420B (zh) | 一种花椒酰胺在制备治疗多发性硬化症的药物中的应用 |